# ü©∫ AYESHA KIANI - COMPLETE CASE STATUS & MOAT APPLICATION

**Patient:** AK | Age 40 | Stage IVB HGSOC  
**MRN:** 1011021118 / 68741392  
**Last Updated:** December 3, 2025  
**Status:** ‚è≥ AWAITING CRITICAL TEST RESULTS (NGS, HRD)

---

## üéØ EXECUTIVE SUMMARY

| Category | Status | Details |
|----------|--------|---------|
| **Diagnosis** | ‚úÖ Confirmed | High-Grade Serous Ovarian Cancer (HGSOC), Stage IVB |
| **Germline Testing** | ‚úÖ Complete | BRCA1/2 NEGATIVE, **MBD4 c.1239delA HOMOZYGOUS** ‚≠ê |
| **Somatic Testing (NGS)** | üî¥ PENDING | ctDNA ordered, awaiting results |
| **HRD Score** | üî¥ PENDING | Myriad myChoice ordered |
| **CA-125 Baseline** | üî¥ PENDING | Must be ordered immediately |
| **Treatment** | ‚è≥ Pre-treatment | Awaiting test results for optimal strategy |

---

## ‚≠ê WHAT WE KNOW - CONFIRMED FINDINGS

### 1. Germline: MBD4 + BRCA1/2 Status

| Gene | Result | Clinical Impact |
|------|--------|-----------------|
| **MBD4** | c.1239delA **HOMOZYGOUS** ‚≠ê | BER pathway completely deficient |
| BRCA1 | Negative | No germline BRCA1 mutation |
| BRCA2 | Negative | No germline BRCA2 mutation |
| 36 other genes | Negative | Ambry CustomNext 38-gene panel |

**MBD4 Homozygous Loss = BER Deficiency:**
```
MBD4 ‚Üí Methyl-CpG Binding Domain Protein 4
     ‚Üí Key enzyme in Base Excision Repair (BER)
     ‚Üí Repairs deaminated bases (G:T mismatches from 5mC‚ÜíT)
     
HOMOZYGOUS LOSS ‚Üí Both alleles non-functional
                ‚Üí Complete BER pathway deficiency
                ‚Üí Cannot repair oxidative DNA damage
                ‚Üí SYNTHETIC LETHAL with PARP inhibition
```

### 2. Somatic (from IHC)

| Marker | Result | Interpretation |
|--------|--------|----------------|
| **TP53** | Strong diffuse + | **MUTANT** (loss of function) |
| ER | 60% + | Estrogen receptor positive |
| PR | 0% | Progesterone receptor negative |
| PAX8 | + | Mullerian origin |
| WT1 | + | Serous differentiation |
| p16 | Strong + | High-grade serous confirmed |

### 3. Disease Extent (PET-CT)

```
STAGE IVB - Extensive Metastatic Disease:
‚îú‚îÄ‚îÄ Primary: Right lower quadrant mass (8 cm, SUV 15)
‚îú‚îÄ‚îÄ Uterine cervix: FDG-avid (SUV 11)
‚îú‚îÄ‚îÄ Nodes: Innumerable abdominopelvic (SUV 8-10)
‚îú‚îÄ‚îÄ Pleura: Bilateral effusions with deposits
‚îú‚îÄ‚îÄ Omentum: Caking
‚îú‚îÄ‚îÄ Left adnexa: Cystic with FDG-avid rim
‚îî‚îÄ‚îÄ Left arm: Soft tissue lesion (3.0 x 2.5 cm)
```

---

## üî¥ WHAT'S PENDING - CRITICAL TESTS AWAITED

### Priority 1: MUST HAVE BEFORE TREATMENT

| Test | Status | Why Critical | Expected Turnaround |
|------|--------|--------------|---------------------|
| **CA-125 Baseline** | üî¥ NOT ORDERED | Cannot track treatment response without baseline | 1-2 days |
| **Somatic NGS (ctDNA)** | ‚è≥ Ordered | Need full mutation profile | 2-3 weeks |
| **HRD Score** | ‚è≥ Ordered | Confirms PARP eligibility | 2-3 weeks |

### Priority 2: IMPORTANT FOR TREATMENT OPTIMIZATION

| Test | Status | Why Important | Expected Turnaround |
|------|--------|---------------|---------------------|
| **MSI/dMMR** | üî¥ NOT ORDERED | MBD4 loss may cause MSI ‚Üí IO eligible | 1-2 weeks |
| **TMB** | Will come with NGS | BER deficiency ‚Üí likely elevated | With NGS |
| **Somatic BRCA1/2** | Will come with NGS | Different from germline | With NGS |

---

## üìã COMPLETE MUTATION CHECKLIST

### Genes We Need From NGS (and why they matter for Ayesha)

#### 1. DNA Repair Pathway (DDR) - CRITICAL for PARP Decision
| Gene | Why Check | If Mutated |
|------|-----------|------------|
| **BRCA1** (somatic) | Different from germline | PARP eligible |
| **BRCA2** (somatic) | Different from germline | PARP eligible |
| **ATM** | DDR pathway | Enhanced platinum/PARP sensitivity |
| **ATR** | Replication stress response | ATR inhibitor trials |
| **CHEK1/CHEK2** | Cell cycle checkpoint | CHK1 inhibitor trials |
| **RAD51C/D** | Homologous recombination | HRD confirmation |
| **PALB2** | BRCA2 partner | HRD confirmation |
| **FANCA/FANCD2** | Fanconi pathway | Platinum sensitivity |

#### 2. TP53 - Confirm Exact Variant
| Gene | Why Check | Expected Finding |
|------|-----------|------------------|
| **TP53** | IHC shows mutant pattern | Likely R175H, R248Q, or R273H (HGSOC hotspots) |

#### 3. Resistance Prediction Genes - VALIDATED (MAPK RR=1.97)
| Gene | Why Check | If Mutated |
|------|-----------|------------|
| **KRAS** | MAPK pathway | 2x platinum resistance risk |
| **NRAS** | MAPK pathway | 2x platinum resistance risk |
| **BRAF** | MAPK pathway | 2x platinum resistance risk |
| **NF1** | RAS regulator | 2.1x platinum resistance risk |
| **MEK1/2** | MAPK pathway | Consider MEK inhibitors |

#### 4. Other Clinically Relevant Genes
| Gene | Why Check | If Mutated |
|------|-----------|------------|
| **PIK3CA** | PI3K pathway | PI3K inhibitor trials |
| **PTEN** | PI3K pathway | PI3K inhibitor trials |
| **MYC** | Amplification | Aggressive biology |
| **CCNE1** | Cyclin E1 | PARP resistance marker |
| **RB1** | Cell cycle | May affect CDK inhibitor response |

#### 5. Drug Efflux (if treatment fails)
| Gene | Why Check | If Altered |
|------|-----------|------------|
| **ABCB1 (MDR1)** | Drug efflux pump | Cross-resistance concern |

---

## üéØ WHAT OUR SYSTEM CAN DO FOR AYESHA

### MOAT 1: Toxicity-Aware Nutrition ‚úÖ READY

**Current Recommendation:**
```
Ayesha on Carboplatin (expected regimen):
‚îú‚îÄ‚îÄ Drug MoA: DNA crosslinks ‚Üí DDR stress
‚îú‚îÄ‚îÄ MBD4 status: Homozygous loss ‚Üí NO BER backup
‚îú‚îÄ‚îÄ Toxicity: Extreme DNA repair stress
‚îÇ
‚îî‚îÄ‚îÄ Recommendation:
    ‚îú‚îÄ‚îÄ NAC 600mg: Post-infusion (glutathione precursor)
    ‚îú‚îÄ‚îÄ Vitamin D: 2000 IU daily (DNA repair support)
    ‚îú‚îÄ‚îÄ Omega-3: 2g daily (anti-inflammatory)
    ‚îî‚îÄ‚îÄ Avoid: Antioxidants DURING infusion (may protect tumor)
```

**Status:** ‚úÖ ACTIONABLE NOW (once treatment starts)

---

### MOAT 2: Resistance Prediction ‚è≥ AWAITING NGS

**What We Validated:**
- MAPK/NF1 mutations ‚Üí 2x platinum resistance (RR=1.97, p<0.05)
- Validated on 469 TCGA-OV patients

**What We Need for Ayesha:**
| Check | From NGS | Action If Present |
|-------|----------|-------------------|
| KRAS mutation | ‚è≥ Pending | Flag 2x resistance risk, earlier PARP switch |
| NRAS mutation | ‚è≥ Pending | Flag 2x resistance risk, earlier PARP switch |
| NF1 mutation | ‚è≥ Pending | Flag 2.1x resistance risk |
| BRAF mutation | ‚è≥ Pending | Consider BRAF/MEK inhibitors |

**Baseline Prediction (without NGS):**
```
MBD4 + TP53 + No MAPK = LOW baseline resistance risk
‚îú‚îÄ‚îÄ BER deficiency ‚Üí HIGH platinum sensitivity
‚îú‚îÄ‚îÄ TP53 loss ‚Üí Checkpoint bypass (favorable for chemo)
‚îî‚îÄ‚îÄ No MAPK mutations detected (IHC only) ‚Üí TBD from NGS
```

**Status:** ‚è≥ PARTIAL - Need NGS for MAPK/NF1 check

---

### MOAT 3: IO Eligibility (TMB/MSI) ‚è≥ AWAITING NGS

**What We Validated:**
- TMB calculation: r=0.933 vs TCGA ground truth
- Classification accuracy: 95.4% for TMB-H (‚â•10 mut/Mb)

**What We Expect for Ayesha:**
```
MBD4 Homozygous Loss ‚Üí BER Deficiency ‚Üí Hypothesis:
‚îú‚îÄ‚îÄ Increased mutation rate (BER can't fix base damage)
‚îú‚îÄ‚îÄ Possibly elevated TMB
‚îú‚îÄ‚îÄ Possibly MSI-High (if MMR also affected)
‚îÇ
‚îî‚îÄ‚îÄ If TMB-H (‚â•10 mut/Mb) OR MSI-H:
    ‚Üí IO (checkpoint inhibitor) eligible
    ‚Üí Pembrolizumab/Nivolumab as option
```

**Status:** ‚è≥ NEED NGS + MSI TESTING

---

### MOAT 4: Trial Matching ‚úÖ READY

**Keywords for Ayesha's Profile:**
```python
TRIAL_KEYWORDS = [
    "MBD4 mutation",
    "BER deficiency",
    "DNA repair deficiency ovarian cancer",
    "PARP inhibitor combination",
    "ATR inhibitor ovarian",
    "CHK1 inhibitor",
    "WEE1 inhibitor",
    "synthetic lethal",
    "TP53 mutant ovarian",
    "platinum sensitive HGSOC"
]
```

**Status:** ‚úÖ READY TO RUN once we confirm HRD status

---

### MOAT 5: PARP Eligibility ‚≠ê STRONGLY INDICATED

**MBD4 + TP53 = SYNTHETIC LETHALITY with PARP:**
```
Normal Cell:
‚îú‚îÄ‚îÄ DNA damage occurs
‚îú‚îÄ‚îÄ BER pathway repairs base damage
‚îú‚îÄ‚îÄ MMR/NER provide backup
‚îî‚îÄ‚îÄ Cell survives

Ayesha's Tumor Cells:
‚îú‚îÄ‚îÄ DNA damage occurs
‚îú‚îÄ‚îÄ BER pathway DISABLED (MBD4 loss)
‚îú‚îÄ‚îÄ If we also block PARP (BER enzyme):
‚îÇ   ‚îî‚îÄ‚îÄ NO DNA repair possible
‚îú‚îÄ‚îÄ Cells die (synthetic lethality)
‚îî‚îÄ‚îÄ Normal cells survive (have working BER)
```

**PARP Recommendation:**
| Drug | Priority | Rationale |
|------|----------|-----------|
| **Olaparib** | ‚≠ê‚≠ê‚≠ê | First-line PARP, approved for HRD+ |
| **Niraparib** | ‚≠ê‚≠ê‚≠ê | Approved regardless of BRCA, may work for MBD4 |
| **Rucaparib** | ‚≠ê‚≠ê | Alternative if above not tolerated |

**Status:** ‚≠ê VERY STRONG INDICATION (awaiting HRD confirmation)

---

## üìä COMPLETE CHECKLIST - WHAT WE NEED BEFORE TREATMENT

### üî¥ IMMEDIATE (This Week)

| Item | Status | Owner | Notes |
|------|--------|-------|-------|
| CA-125 baseline | üî¥ NOT DONE | Oncologist | CRITICAL - order today |
| CBC, CMP, LFTs | ‚ùì Unknown | Oncologist | Standard pre-chemo |
| Albumin, pre-albumin | ‚ùì Unknown | Oncologist | Nutritional status |

### ‚è≥ PENDING (2-3 Weeks)

| Item | Status | Owner | Notes |
|------|--------|-------|-------|
| ctDNA/Somatic NGS | ‚è≥ Ordered | Lab | Full mutation profile |
| HRD Score (myChoice) | ‚è≥ Ordered | Myriad | PARP eligibility |
| MSI/dMMR testing | üî¥ NOT ORDERED | Oncologist | ORDER with NGS |

### ‚úÖ COMPLETED

| Item | Status | Result |
|------|--------|--------|
| Germline panel (38 genes) | ‚úÖ | BRCA1/2 negative |
| MBD4 analysis | ‚úÖ | c.1239delA HOMOZYGOUS ‚≠ê |
| Cytology/IHC | ‚úÖ | HGSOC, TP53 mutant, ER+ |
| PET-CT staging | ‚úÖ | Stage IVB, extensive disease |

---

## üéØ DECISION TREE - ONCE RESULTS ARRIVE

### Scenario 1: HRD+ (Expected)
```
HRD Score ‚â•42:
‚îú‚îÄ‚îÄ Confirms PARP eligibility
‚îú‚îÄ‚îÄ Treatment: Carboplatin/Paclitaxel ‚Üí IDS ‚Üí PARP maintenance
‚îú‚îÄ‚îÄ PARP choice: Olaparib or Niraparib
‚îî‚îÄ‚îÄ Duration: 2-3 years or until progression
```

### Scenario 2: HRD- (Unlikely given MBD4)
```
HRD Score <42:
‚îú‚îÄ‚îÄ Does NOT rule out PARP benefit (MBD4 is different mechanism)
‚îú‚îÄ‚îÄ Consider: Bevacizumab maintenance OR
‚îú‚îÄ‚îÄ Consider: PARP trial for non-BRCA/non-HRD
‚îî‚îÄ‚îÄ MBD4 synthetic lethality may still work
```

### Scenario 3: MAPK/NF1 Mutation Found
```
KRAS/NRAS/BRAF/NF1 mutated:
‚îú‚îÄ‚îÄ Flag 2x platinum resistance risk
‚îú‚îÄ‚îÄ More intensive monitoring (CA-125, ctDNA)
‚îú‚îÄ‚îÄ Earlier consideration of PARP switch
‚îú‚îÄ‚îÄ Identify ATR/CHK1/MEK trials as backup
‚îî‚îÄ‚îÄ Consider combination therapy
```

### Scenario 4: TMB-H or MSI-H
```
TMB ‚â•10 mut/Mb OR MSI-High:
‚îú‚îÄ‚îÄ IO (checkpoint inhibitor) eligible
‚îú‚îÄ‚îÄ Consider: Pembrolizumab + standard chemo
‚îú‚îÄ‚îÄ Or: IO + PARP combination trial
‚îî‚îÄ‚îÄ Mechanism vector: IO pathway = 1.0
```

---

## üìã OUR SYSTEM'S ACTION ITEMS

### When NGS Results Arrive:
```
‚òê Extract all mutations from NGS report
‚òê Check MAPK pathway: KRAS, NRAS, BRAF, NF1, MEK1/2
‚òê Check DDR pathway: somatic BRCA1/2, ATM, ATR, CHEK1/2
‚òê Calculate TMB (if raw data available)
‚òê Update resistance prediction
‚òê Update IO eligibility
‚òê Re-run trial matching with full mutation profile
‚òê Update nutrition recommendations based on full profile
```

### When HRD Results Arrive:
```
‚òê Confirm HRD status (‚â•42 = positive)
‚òê Update PARP recommendation confidence
‚òê Finalize maintenance strategy
‚òê Update trial matching for HRD trials
```

### When CA-125 Baseline Available:
```
‚òê Store as baseline value
‚òê Set up monitoring alerts
‚òê Configure response tracking
‚òê Enable early recurrence detection
```

---

## üî¨ VALIDATED CAPABILITIES FOR AYESHA

| Capability | Validation Status | Ready for Ayesha |
|------------|-------------------|------------------|
| TMB Calculation | ‚úÖ r=0.933, 95.4% accuracy | ‚è≥ Need NGS data |
| MAPK Resistance | ‚úÖ RR=1.97, p<0.05 | ‚è≥ Need NGS data |
| Toxicity Nutrition | ‚úÖ E2E tests passing | ‚úÖ Ready now |
| PARP Recommendation | ‚úÖ Literature-backed | ‚≠ê Strong indication |
| Trial Matching | ‚úÖ Operational | ‚è≥ Need HRD confirmation |

---

## üìä AYESHA'S KEY NUMBERS TO TRACK

| Biomarker | Baseline | Target | Monitoring |
|-----------|----------|--------|------------|
| CA-125 | ‚ùì TBD | <35 U/mL | Every cycle |
| HRD Score | ‚è≥ Pending | ‚â•42 = eligible | Once |
| TMB | ‚è≥ Pending | ‚â•10 = IO eligible | Once |
| MSI | ‚ùì Not ordered | MSI-H = IO eligible | Once |
| Hemoglobin | ‚ùì | >10 g/dL | Every cycle |
| ANC | ‚ùì | >1.5 √ó 10‚Åπ/L | Every cycle |
| Creatinine | ‚ùì | <1.2 mg/dL | Every cycle |

---

## üö® GAPS IDENTIFIED - MUST CLOSE

| Gap | Impact | Action Required |
|-----|--------|-----------------|
| No CA-125 baseline | Cannot track response | **ORDER IMMEDIATELY** |
| No MSI testing | May miss IO eligibility | Order with NGS |
| NGS pending | Cannot complete resistance prediction | Wait for results |
| HRD pending | Cannot finalize PARP strategy | Wait for results |
| No ctDNA baseline | Cannot do MRD monitoring | Order baseline ctDNA |

---

## üìù SUMMARY

**What We KNOW:**
- ‚≠ê **MBD4 c.1239delA HOMOZYGOUS** ‚Üí BER pathway completely disabled
- ‚≠ê **TP53 mutant** ‚Üí Checkpoint bypass
- Stage IVB HGSOC with extensive carcinomatosis
- Germline BRCA1/2 negative (but somatic TBD)
- **This is a SYNTHETIC LETHAL combination** ‚Üí PARP inhibitors indicated

**What We're WAITING FOR:**
- üî¥ NGS (ctDNA) ‚Üí Full mutation profile, TMB, MAPK status
- üî¥ HRD Score ‚Üí PARP eligibility confirmation
- üî¥ CA-125 Baseline ‚Üí Response monitoring
- üî¥ MSI Testing ‚Üí IO eligibility

**What We CAN DO NOW:**
- ‚úÖ Toxicity-protective nutrition (NAC, Vitamin D)
- ‚úÖ Trial keyword search (MBD4, BER deficiency)
- ‚úÖ PARP recommendation (very strong indication)

**What We'll Do When Results Arrive:**
- Apply validated MAPK resistance prediction
- Calculate TMB with validated method (r=0.933)
- Determine IO eligibility
- Complete trial matching
- Finalize maintenance strategy

---

**Document Status:** Living document  
**Next Update:** When NGS, HRD, or CA-125 results arrive  
**Contact:** CrisPRO.ai Oncology Team

---